TEMIT HY24: revenue income down 31% even as NAV loss narrows to NZ$11.9m

What changed

Revenue (dividend income from the emerging-markets portfolio) fell 31.2% to NZ$38.3m from NZ$55.7m. The bottom-line result improved markedly: NPAT was a NZ$11.9m loss versus a NZ$177.3m loss in HY23, a 93.3% narrowing that reflects a much smaller capital/valuation hit on the portfolio rather than any income tailwind. Operating cash inflow dropped 21.1% to NZ$37.3m. Cash on hand fell NZ$36.4m to NZ$130.7m, while total liabilities dropped from NZ$150.6m to NZ$100.3m, leaving the trust in a stronger net-cash position. Total assets rose 3.4% to NZ$1.9b. The NAV total return was -0.5%, effectively in line with the MSCI Emerging Markets benchmark (also -0.5%).

What matters

• The income line, not the headline loss, is the real read. Because this is an investment trust, the 93.3% NPAT "improvement" almost entirely reflects smaller unrealised portfolio losses, not operating performance. The durable signal is the 31.2% fall in dividend income to NZ$38.3m and net revenue earnings of 3.34 pence per share, which directly constrains the sustainable dividend.
• Benchmark-relative performance was neutral. NAV total return matched the index at -0.5%, so HY24 does not demonstrate active-management alpha in either direction — it is a period where the vehicle neither added to nor subtracted from passive EM exposure after fees.
• Receivables built materially against a falling revenue base. Trade debtors rose 29.7% to NZ$10.6m while revenue fell, lifting receivables days from ~26.8 to ~50.4 — a meaningful timing drag on cash.

Expectations

No quantified earnings target has been provided, and the Chairman explicitly said it is too early to predict full-year earnings while noting the trust "usually earns the majority of its revenue in the second half." Annualising HY24 revenue naively gives ~NZ$76.7m, but that almost certainly understates the full-year income outcome given the disclosed second-half skew. What the release does support: a weaker full-year dividend-income run-rate than FY23 unless H2 dividend receipts recover sharply. What it does not support: any assessment of alpha versus the benchmark over the rest of the year, since HY24 was effectively a benchmark-matching period.

Quality of result

The earnings improvement is almost entirely balance-sheet-assisted — it reflects a smaller mark-to-market drawdown on the portfolio rather than stronger underlying income. On the durable side, the trust remains in net cash, liabilities fell 33.4%, and operating cash flow, though down 21.1%, still exceeded the reported loss. Against that, cash conversion deteriorated: receivables days roughly doubled, and OCF fell faster than the underlying dividend-income fundamentals would suggest on a clean basis. The tax line also cannot be cleanly isolated in the extracted data (prior-year implied effective rate ~3.9%), so PBT-versus-NPAT attribution has to be read with caution.

Unresolved

• What drove the 31.2% decline in dividend income — portfolio rotation, cuts at underlying holdings, or timing of ex-dividend dates falling into H2?
• What interim dividend has actually been declared for HY24, and how does it compare with the 3.34 pence per share of net revenue earnings?
• Why did receivables days jump from ~27 to ~50 on a smaller revenue base, and is this purely a timing effect that reverses in H2?
• What is NTA per share and the current discount/premium to NAV — not extracted, so valuation cannot be framed.
• What portion of the NZ$36.4m cash decline was returned to shareholders versus redeployed into the portfolio?

This briefing cannot assess portfolio-level stock selection, the discount to NAV, or the sustainability of the dividend, because holdings-level data, NTA per share, and the declared interim distribution were not provided.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.